Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris
Public ClinicalTrials.gov record NCT02938494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, in the Treatment of Acne Vulgaris
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris
Study identification
- NCT ID
- NCT02938494
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2015
- Primary completion
- Jun 30, 2016
- Completion
- Aug 31, 2016
- Last update posted
- Sep 22, 2020
2015 – 2016
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valeant Site 03 | Encinitas | California | 92024 | — |
| Valeant Site 04 | Fremont | California | 94538 | — |
| Valeant Site 06 | Los Angeles | California | 90036 | — |
| Valeant Site 14 | Sacramento | California | 95819 | — |
| Valeant Site 01 | Santa Monica | California | 90404 | — |
| Valeant Site 05 | Colorado Springs | Colorado | 80915 | — |
| Valeant Site 08 | Coral Gables | Florida | 33146 | — |
| Valeant Site 10 | Miami | Florida | 33175 | — |
| Valeant Site 09 | Miramar | Florida | 33027 | — |
| Valeant Site 12 | Louisville | Kentucky | 40202 | — |
| Valeant Site 13 | Louisville | Kentucky | 40217 | — |
| Valeant Site 02 | Rockville | Maryland | 20850 | — |
| Valeant Site 07 | Fridley | Minnesota | 55432 | — |
| Valeant Site 16 | Chapel Hill | North Carolina | 27517 | — |
| Valeant Site 15 | High Point | North Carolina | 27262 | — |
| Valeant Site 11 | Philadelphia | Pennsylvania | 19103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02938494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02938494 live on ClinicalTrials.gov.